Phase III trial of IL-2.
D000163:Acquired Immunodeficiency Syndrome / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D019380:Anti-HIV Agents / Q000276:immunology / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count / Q000187:drug effects; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D018450:Disease Progression; D004359:Drug Therapy, Combination; D006801:Humans; D007376:Interleukin-2 / Q000031:analogs & derivatives* / Q000276:immunology / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000276:immunology / Q000627:therapeutic use; D019562:Viral Load
D019380:Anti-HIV Agents; D007376:Interleukin-2; D011994:Recombinant Proteins; C082598:aldesleukin